ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Thiotepa
Bladder, kidney, and other urologic cancers
Breast cancer
Gynecologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Thiotepa Rx

Generic Name and Formulations:
Thiotepa 15mg; per vial; lyophilized pwd for IV, intravesical, or intracavitary administration after reconstitution.

Company:
Various generic manufacturers

Therapeutic Use:

Indications for Thiotepa:

Superficial papillary carcinoma of the urinary bladder. Intracavitary effusion due to neoplasm of serosal cavities.

Adult:

Avoid fluids 8–12 hrs prior to treatment. 60mg once weekly for 4 weeks; may repeat up to a total of 3 courses. Retain in bladder for 2 hours. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.

Children:

Not recommended.

Contraindications:

Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.

Warnings/Precautions:

Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions:

Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.

Note:

Formerly known under the brand name Thioplex.

How Supplied:

Contact supplier.

Indications for Thiotepa:

Adenocarcinomas of the breast. Intracavitary effusion due to neoplasm of serosal cavities.

Adult:

0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.

Children:

Not recommended.

Contraindications:

Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.

Warnings/Precautions:

Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions:

Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.

Note:

Formerly known under the brand name Thioplex.

How Supplied:

Contact supplier.

Indications for Thiotepa:

Adenocarcinomas of the ovary. Intracavitary effusion due to neoplasm of serosal cavities.

Adult:

0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.

Children:

Not recommended.

Contraindications:

Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.

Warnings/Precautions:

Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions:

Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.

Note:

Formerly known under the brand name Thioplex.

How Supplied:

Contact supplier.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs